IRF6 and metabolic disease: Given that quantification of shifts in plasma lipoprotein size has provided profound insights into the etiology of multiple metabolic disorders (20, 21, 68), future work will focus on molecular profiling of CSF-Lps to identify functionally relevant subspecies in individuals suffering from neurodegenerative disorders.